IBDEI03W ; ; 09-MAY-2014
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;MAY 09, 2014
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,4900,2)
 ;;=^293664
 ;;^UTILITY(U,$J,358.3,4901,0)
 ;;=280.9^^33^368^83
 ;;^UTILITY(U,$J,358.3,4901,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,4901,1,4,0)
 ;;=4^280.9
 ;;^UTILITY(U,$J,358.3,4901,1,5,0)
 ;;=5^Iron Defic Anemia(Unspecified)
 ;;^UTILITY(U,$J,358.3,4901,2)
 ;;=^276946
 ;;^UTILITY(U,$J,358.3,4902,0)
 ;;=285.1^^33^368^81
 ;;^UTILITY(U,$J,358.3,4902,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,4902,1,4,0)
 ;;=4^285.1
 ;;^UTILITY(U,$J,358.3,4902,1,5,0)
 ;;=5^Iron Defic Anemia d/t Acute Blood Loss
 ;;^UTILITY(U,$J,358.3,4902,2)
 ;;=^267986
 ;;^UTILITY(U,$J,358.3,4903,0)
 ;;=280.0^^33^368^82
 ;;^UTILITY(U,$J,358.3,4903,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,4903,1,4,0)
 ;;=4^280.0
 ;;^UTILITY(U,$J,358.3,4903,1,5,0)
 ;;=5^Iron Defic Anemia d/t Chr Blood Loss
 ;;^UTILITY(U,$J,358.3,4903,2)
 ;;=^267971
 ;;^UTILITY(U,$J,358.3,4904,0)
 ;;=281.9^^33^368^101
 ;;^UTILITY(U,$J,358.3,4904,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,4904,1,4,0)
 ;;=4^281.9
 ;;^UTILITY(U,$J,358.3,4904,1,5,0)
 ;;=5^Nutritional Anemia
 ;;^UTILITY(U,$J,358.3,4904,2)
 ;;=^123801
 ;;^UTILITY(U,$J,358.3,4905,0)
 ;;=281.0^^33^368^121
 ;;^UTILITY(U,$J,358.3,4905,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,4905,1,4,0)
 ;;=4^281.0
 ;;^UTILITY(U,$J,358.3,4905,1,5,0)
 ;;=5^Vit B12 Deficiency (Pernicious Anemia)
 ;;^UTILITY(U,$J,358.3,4905,2)
 ;;=^7161
 ;;^UTILITY(U,$J,358.3,4906,0)
 ;;=282.60^^33^368^108
 ;;^UTILITY(U,$J,358.3,4906,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,4906,1,4,0)
 ;;=4^282.60
 ;;^UTILITY(U,$J,358.3,4906,1,5,0)
 ;;=5^Sickle-Cell Anemia
 ;;^UTILITY(U,$J,358.3,4906,2)
 ;;=^7188
 ;;^UTILITY(U,$J,358.3,4907,0)
 ;;=282.62^^33^368^109
 ;;^UTILITY(U,$J,358.3,4907,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,4907,1,4,0)
 ;;=4^282.62
 ;;^UTILITY(U,$J,358.3,4907,1,5,0)
 ;;=5^Sickle-Cell With Crisis
 ;;^UTILITY(U,$J,358.3,4907,2)
 ;;=^267982
 ;;^UTILITY(U,$J,358.3,4908,0)
 ;;=281.1^^33^368^122
 ;;^UTILITY(U,$J,358.3,4908,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,4908,1,4,0)
 ;;=4^281.1
 ;;^UTILITY(U,$J,358.3,4908,1,5,0)
 ;;=5^Vit B12 Deficiency(Dietary)
 ;;^UTILITY(U,$J,358.3,4908,2)
 ;;=^267974
 ;;^UTILITY(U,$J,358.3,4909,0)
 ;;=286.7^^33^368^51
 ;;^UTILITY(U,$J,358.3,4909,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,4909,1,4,0)
 ;;=4^286.7
 ;;^UTILITY(U,$J,358.3,4909,1,5,0)
 ;;=5^Coagulation Defect(Any),Acquired
 ;;^UTILITY(U,$J,358.3,4909,2)
 ;;=^2235
 ;;^UTILITY(U,$J,358.3,4910,0)
 ;;=289.9^^33^368^118
 ;;^UTILITY(U,$J,358.3,4910,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,4910,1,4,0)
 ;;=4^289.9
 ;;^UTILITY(U,$J,358.3,4910,1,5,0)
 ;;=5^Thrombocytosis, Essential
 ;;^UTILITY(U,$J,358.3,4910,2)
 ;;=^55344
 ;;^UTILITY(U,$J,358.3,4911,0)
 ;;=451.9^^33^368^119
 ;;^UTILITY(U,$J,358.3,4911,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,4911,1,4,0)
 ;;=4^451.9
 ;;^UTILITY(U,$J,358.3,4911,1,5,0)
 ;;=5^Thrombophlebitis 
 ;;^UTILITY(U,$J,358.3,4911,2)
 ;;=^93357
 ;;^UTILITY(U,$J,358.3,4912,0)
 ;;=446.6^^33^368^120
 ;;^UTILITY(U,$J,358.3,4912,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,4912,1,4,0)
 ;;=4^446.6
 ;;^UTILITY(U,$J,358.3,4912,1,5,0)
 ;;=5^Thrombotic Thrombocytopenic Purpura(TTP)
 ;;^UTILITY(U,$J,358.3,4912,2)
 ;;=^119061
 ;;^UTILITY(U,$J,358.3,4913,0)
 ;;=286.4^^33^368^123
 ;;^UTILITY(U,$J,358.3,4913,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,4913,1,4,0)
 ;;=4^286.4
 ;;^UTILITY(U,$J,358.3,4913,1,5,0)
 ;;=5^Von Willebrand's Disease
 ;;^UTILITY(U,$J,358.3,4913,2)
 ;;=^127267
 ;;^UTILITY(U,$J,358.3,4914,0)
 ;;=204.00^^33^368^2
 ;;^UTILITY(U,$J,358.3,4914,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,4914,1,4,0)
 ;;=4^204.00
 ;;^UTILITY(U,$J,358.3,4914,1,5,0)
 ;;=5^ALL w/o Remission
 ;;^UTILITY(U,$J,358.3,4914,2)
 ;;=^267521
 ;;^UTILITY(U,$J,358.3,4915,0)
 ;;=204.01^^33^368^1
 ;;^UTILITY(U,$J,358.3,4915,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,4915,1,4,0)
 ;;=4^204.01
 ;;^UTILITY(U,$J,358.3,4915,1,5,0)
 ;;=5^ALL in Remission
 ;;^UTILITY(U,$J,358.3,4915,2)
 ;;=^267522
 ;;^UTILITY(U,$J,358.3,4916,0)
 ;;=204.10^^33^368^26
 ;;^UTILITY(U,$J,358.3,4916,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,4916,1,4,0)
 ;;=4^204.10
 ;;^UTILITY(U,$J,358.3,4916,1,5,0)
 ;;=5^CLL w/o Remission
 ;;^UTILITY(U,$J,358.3,4916,2)
 ;;=^267523
 ;;^UTILITY(U,$J,358.3,4917,0)
 ;;=204.11^^33^368^24
 ;;^UTILITY(U,$J,358.3,4917,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,4917,1,4,0)
 ;;=4^204.11
 ;;^UTILITY(U,$J,358.3,4917,1,5,0)
 ;;=5^CLL in Remission
 ;;^UTILITY(U,$J,358.3,4917,2)
 ;;=^267524
 ;;^UTILITY(U,$J,358.3,4918,0)
 ;;=202.41^^33^368^73
 ;;^UTILITY(U,$J,358.3,4918,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,4918,1,4,0)
 ;;=4^202.41
 ;;^UTILITY(U,$J,358.3,4918,1,5,0)
 ;;=5^Hairy Cell Leukemia,Unspec Site
 ;;^UTILITY(U,$J,358.3,4918,2)
 ;;=^267472
 ;;^UTILITY(U,$J,358.3,4919,0)
 ;;=201.90^^33^368^80
 ;;^UTILITY(U,$J,358.3,4919,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,4919,1,4,0)
 ;;=4^201.90
 ;;^UTILITY(U,$J,358.3,4919,1,5,0)
 ;;=5^Hodgkin's Lymphoma,Unspec Type & Site
 ;;^UTILITY(U,$J,358.3,4919,2)
 ;;=^267430
 ;;^UTILITY(U,$J,358.3,4920,0)
 ;;=785.6^^33^368^86
 ;;^UTILITY(U,$J,358.3,4920,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,4920,1,4,0)
 ;;=4^785.6
 ;;^UTILITY(U,$J,358.3,4920,1,5,0)
 ;;=5^Lymphadenopathy
 ;;^UTILITY(U,$J,358.3,4920,2)
 ;;=^72368
 ;;^UTILITY(U,$J,358.3,4921,0)
 ;;=200.20^^33^368^89
 ;;^UTILITY(U,$J,358.3,4921,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,4921,1,4,0)
 ;;=4^200.20
 ;;^UTILITY(U,$J,358.3,4921,1,5,0)
 ;;=5^Lymphoma,Burkett's,Unspecified Sites
 ;;^UTILITY(U,$J,358.3,4921,2)
 ;;=^17529
 ;;^UTILITY(U,$J,358.3,4922,0)
 ;;=202.00^^33^368^88
 ;;^UTILITY(U,$J,358.3,4922,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,4922,1,4,0)
 ;;=4^202.00
 ;;^UTILITY(U,$J,358.3,4922,1,5,0)
 ;;=5^Lymphoma, Low-Grade, Unspec Site
 ;;^UTILITY(U,$J,358.3,4922,2)
 ;;=^72606
 ;;^UTILITY(U,$J,358.3,4923,0)
 ;;=200.10^^33^368^87
 ;;^UTILITY(U,$J,358.3,4923,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,4923,1,4,0)
 ;;=4^200.10
 ;;^UTILITY(U,$J,358.3,4923,1,5,0)
 ;;=5^Lymphoma, Int Or High Grade, Unspec Site
 ;;^UTILITY(U,$J,358.3,4923,2)
 ;;=^175886
 ;;^UTILITY(U,$J,358.3,4924,0)
 ;;=273.3^^33^368^90
 ;;^UTILITY(U,$J,358.3,4924,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,4924,1,4,0)
 ;;=4^273.3
 ;;^UTILITY(U,$J,358.3,4924,1,5,0)
 ;;=5^Macroglobulinemia
 ;;^UTILITY(U,$J,358.3,4924,2)
 ;;=^73013
 ;;^UTILITY(U,$J,358.3,4925,0)
 ;;=203.00^^33^368^99
 ;;^UTILITY(U,$J,358.3,4925,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,4925,1,4,0)
 ;;=4^203.00
 ;;^UTILITY(U,$J,358.3,4925,1,5,0)
 ;;=5^Multiple Myeloma W/O Rem
 ;;^UTILITY(U,$J,358.3,4925,2)
 ;;=^267514
 ;;^UTILITY(U,$J,358.3,4926,0)
 ;;=203.01^^33^368^98
 ;;^UTILITY(U,$J,358.3,4926,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,4926,1,4,0)
 ;;=4^203.01
 ;;^UTILITY(U,$J,358.3,4926,1,5,0)
 ;;=5^Multiple Myeloma In Remission
 ;;^UTILITY(U,$J,358.3,4926,2)
 ;;=^267515
 ;;^UTILITY(U,$J,358.3,4927,0)
 ;;=238.6^^33^368^102
 ;;^UTILITY(U,$J,358.3,4927,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,4927,1,4,0)
 ;;=4^238.6
 ;;^UTILITY(U,$J,358.3,4927,1,5,0)
 ;;=5^Plasmacytoma Nos
 ;;^UTILITY(U,$J,358.3,4927,2)
 ;;=^81973
 ;;^UTILITY(U,$J,358.3,4928,0)
 ;;=205.00^^33^368^5
 ;;^UTILITY(U,$J,358.3,4928,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,4928,1,4,0)
 ;;=4^205.00
 ;;^UTILITY(U,$J,358.3,4928,1,5,0)
 ;;=5^AML w/o Remission
 ;;^UTILITY(U,$J,358.3,4928,2)
 ;;=^267531
 ;;^UTILITY(U,$J,358.3,4929,0)
 ;;=205.01^^33^368^4
 ;;^UTILITY(U,$J,358.3,4929,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,4929,1,4,0)
 ;;=4^205.01
 ;;^UTILITY(U,$J,358.3,4929,1,5,0)
 ;;=5^AML in Remission
 ;;^UTILITY(U,$J,358.3,4929,2)
 ;;=^267532
 ;;^UTILITY(U,$J,358.3,4930,0)
 ;;=205.10^^33^368^29
 ;;^UTILITY(U,$J,358.3,4930,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,4930,1,4,0)
 ;;=4^205.10
 ;;^UTILITY(U,$J,358.3,4930,1,5,0)
 ;;=5^CML w/o Remission
 ;;^UTILITY(U,$J,358.3,4930,2)
 ;;=^267533
 ;;^UTILITY(U,$J,358.3,4931,0)
 ;;=205.11^^33^368^28
 ;;^UTILITY(U,$J,358.3,4931,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,4931,1,4,0)
 ;;=4^205.11
 ;;^UTILITY(U,$J,358.3,4931,1,5,0)
 ;;=5^CML in Remission
 ;;^UTILITY(U,$J,358.3,4931,2)
 ;;=^267534
 ;;^UTILITY(U,$J,358.3,4932,0)
 ;;=289.0^^33^368^52
 ;;^UTILITY(U,$J,358.3,4932,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,4932,1,4,0)
 ;;=4^289.0
 ;;^UTILITY(U,$J,358.3,4932,1,5,0)
 ;;=5^Erthryocytosis, Secondary
 ;;^UTILITY(U,$J,358.3,4932,2)
 ;;=^186856
 ;;^UTILITY(U,$J,358.3,4933,0)
 ;;=238.4^^33^368^103
 ;;^UTILITY(U,$J,358.3,4933,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,4933,1,4,0)
 ;;=4^238.4
 ;;^UTILITY(U,$J,358.3,4933,1,5,0)
 ;;=5^Polycytheria Rubra Vera
 ;;^UTILITY(U,$J,358.3,4933,2)
 ;;=^96105
 ;;^UTILITY(U,$J,358.3,4934,0)
 ;;=V58.61^^33^368^124
 ;;^UTILITY(U,$J,358.3,4934,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,4934,1,4,0)
 ;;=4^V58.61
 ;;^UTILITY(U,$J,358.3,4934,1,5,0)
 ;;=5^Warfarin/Coumadin Use
 ;;^UTILITY(U,$J,358.3,4934,2)
 ;;=Warfarin/Coumadin Use^303459
 ;;^UTILITY(U,$J,358.3,4935,0)
 ;;=282.49^^33^368^116
 ;;^UTILITY(U,$J,358.3,4935,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,4935,1,4,0)
 ;;=4^282.49
 ;;^UTILITY(U,$J,358.3,4935,1,5,0)
 ;;=5^Thalassemia Nec
 ;;^UTILITY(U,$J,358.3,4935,2)
 ;;=^329910
 ;;^UTILITY(U,$J,358.3,4936,0)
 ;;=289.89^^33^368^18
 ;;^UTILITY(U,$J,358.3,4936,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,4936,1,4,0)
 ;;=4^289.89
 ;;^UTILITY(U,$J,358.3,4936,1,5,0)
 ;;=5^Blood Diseases Nec
 ;;^UTILITY(U,$J,358.3,4936,2)
 ;;=^329887
 ;;^UTILITY(U,$J,358.3,4937,0)
 ;;=238.79^^33^368^85
 ;;^UTILITY(U,$J,358.3,4937,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,4937,1,4,0)
 ;;=4^238.79
 ;;^UTILITY(U,$J,358.3,4937,1,5,0)
 ;;=5^Lymph/Hematpoietc Tis NEC
 ;;^UTILITY(U,$J,358.3,4937,2)
 ;;=^334033
 ;;^UTILITY(U,$J,358.3,4938,0)
 ;;=287.30^^33^368^104
 ;;^UTILITY(U,$J,358.3,4938,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,4938,1,4,0)
 ;;=4^287.30
